BT200
Phase 3Small molecule
BT200 is one of 8 small molecule programs targeting Von Willebrand disease. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
10 competitors in Von Willebrand Disease
#DrugCompanyPhaseTrials
1Advate
TakedaPhase 3
Vonicog Alfa
TakedaPhase 3
Antihemophilic Factor (recombinant)
TakedaPhase 3
BT200
BBand Therapeutics
Phase 3
VGA039
VVega Therapeutics, Inc
Phase 3
Activated Prothrombin Complex Concentrate
RochePreclinical
Recombinant Interferon Alfa 2a
RochePreclinical
Von Willebrand Factor Concentrates
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Von Willebrand disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BT200. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBand Therapeutics